Informed Consent and the Elusive Dichotomy between Standard and Experimental Therapy

By Noah, Lars | American Journal of Law & Medicine, January 1, 2002 | Go to article overview

Informed Consent and the Elusive Dichotomy between Standard and Experimental Therapy


Noah, Lars, American Journal of Law & Medicine


I. INTRODUCTION

A rich academic literature exists about issues of informed consent in medical care, and, to a lesser extent, about a variety of issues posed by human experimentation. Most commentators regard patient autonomy as a desirable-- though in practice often unattainable-goal, and near unanimity exists about the necessity for even fuller disclosure before experimenting on subjects. Although this Article intentionally side-steps the broader debate about informed consent, it challenges the conventional wisdom that special disclosure rules should apply in the experimental context.

Clinical trials have become big business. Estimates suggest that as many as twenty million Americans have enrolled in formal biomedical studies,1 though, as a measure of the full scope of medical experimentation on humans, that figure may represent only the proverbial tip of the iceberg. Historically, sponsors of clinical trials recruited subjects informally, counting on word of mouth among physicians and also perhaps posting flyers around college campuses. Nowadays, sponsors run national television advertisements and host Internet sites,2 and they also may offer IMAGE FORMULA5

financial incentives to fanily for recruiting subjects from among their existing patients.3

Clinical trials have proliferated in recent years for a variety of reasons. In part, the total volume of biomedical research and development has increased substantially, resulting in a greater number and complexity of new investigational products; in part, federal regulatory requirements for proof of safety and effectiveness have expanded;4 and, in part, patients have become more interested in participating as research subjects, either because their conditions have not responded to existing treatments or because they lack the insurance coverage and resources to afford standard treatments.5 In 1997, reacting to these developments, Congress instructed the National Institutes of Health (NIH) to maintain an Internet site designed for patients seeking ongoing clinical trials in which to enroll.6

Do patients who decide to enroll in clinical trials really understand the nature of these experiments? Federal regulatory agencies have created elaborate protections for human subjects, and a requirement to secure informed consent occupies a central place in these systems. In contrast, outside of the context of clinical trials, federal regulatory agencies have done little to insist that physicians secure informed consent from their patients, instead leaving that task to state tort law. Over the last several decades, medical malpractice doctrine has expanded the disclosure obligations of physicians, but the courts have struggled when asked to apply these rules in the context of experimental procedures. This should come as no surprise, however, because no distinct line separates standard and experimental treatment.

To a greater or lesser extent, all medical interventions have an experimental quality to them. Physicians try things out on their patients all of the time. In many instances, we hope, they do so based on well-grounded confidence in the likely utility of a particular therapy, though even then the variability in patient response may disappoint our expectations. In far too many instances, unfortunately, physicians select interventions that remain poorly understood. Even for those therapeutic choices subject to federal licensing requirements, particularly IMAGE FORMULA8

pharmaceuticals, product approval does not define the point at which an investigational intervention passes the threshold into standard therapy. Instead, the research phase continues after licensure, both in the sense that more safety data accumulates and insofar as physicians may improvise when using a product in ways not originally contemplated. Conversely, an investigational product may become the standard of care even before federal regulators bestow their blessing on a particular use. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Informed Consent and the Elusive Dichotomy between Standard and Experimental Therapy
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.